Monitoring the chemotherapeutic response in primary lung cancer using 99mTc-MIBI SPET

Basit Öğe Kaydı
dc.authoridCermik, Tevfik Fikret/0000-0001-7622-7277
dc.authoridgültekin, aziz/0000-0002-0311-8077
dc.authoridKarlikaya, Celal/0000-0001-7084-4987
dc.authorwosidCermik, Tevfik Fikret/A-9694-2018
dc.authorwosidgültekin, aziz/Q-9820-2018
dc.authorwosidKarlikaya, Celal/JMR-3834-2023
dc.contributor.authorYüksel, M
dc.contributor.authorÇermik, TF
dc.contributor.authorKarlikaya, C
dc.contributor.authorSalan, A
dc.contributor.authorÇakir, E
dc.contributor.authorGültekin, A
dc.contributor.authorBerkarda, F
dc.date.accessioned2024-06-12T11:07:53Z
dc.date.available2024-06-12T11:07:53Z
dc.date.issued2001
dc.departmentTrakya Üniversitesien_US
dc.descriptionEANM Congress -- SEP 02-06, 2000 -- PARIS, FRANCEen_US
dc.description.abstractPrediction and evaluation of the response to chemotherapy (CTx) are important for the correct and cost-effective treatment of patients with primary lung cancer. Although fluorine-18 fluorodeoxyglucose. positron emission tomography (FDG-PET) is accepted as the most useful and accurate nuclear medicine technique for this purpose, its expense and limited availability restrict its use. Compared with PET agents, technetium-99m methoxyisobutylisonitrile (MIBI), which is used in nuclear oncology, is cheaper and available in any nuclear medicine clinic. With this in mind, in this study we aimed to evaluate the role of Te-99m-MIBI in monitoring the chemotherapeutic response in primary lung cancer. Twenty patients with primary lung cancer underwent Tc-99m-MIBI single-photon emission tomography (SPET) at 15 min (early) and 3-4 h (delayed) after injection of the tracer. All patients underwent 99mTc-MIBI SPET study twice: before and after the 3rd cycle of CTx. Patients were divided into two groups, responders [R(+), n=10] and nonresponders [R(-), n=10], according to the change in tumour size on CT scan taken 2 weeks after the last cycle of the CTx. From the SPET images early and delayed tumour/lung ratios (ER and DR) were obtained before and after CTx. In the R(+) group, ER and DR decreased significantly after CTx, from 3.28 +/-1.55 to 1.78 +/-0.72 (P <0.04) and from 3.23 +/-1.55 to 2.0 +/-0.88 (P <0.05), respectively. However, in the R(-) group, while ER showed a slight and statistically insignificant increase after CTx (from 2.51 +/-1.23 to 2.65 +/-1.86), DR increased significantly, from 2.74 +/-1.37 to 3.27 +/-2.31 (P <0.03). The percentage decreases in ER and DR in the R(+) group after CTx was significantly higher than that in the R(-) group: 34.36%+/- 26.7% vs -13.78%+/- 27.58% (P <0.0002) and 29.45%+/- 25.23% vs -18.58%+/- 20.51% (P <0.0005), respectively. Using a decrease of greater than or equal to 10% as a threshold for monitoring the chemotherapeutic response, Te-99m-MIBI had a sensitivity of 90% and a specificity of 100%. We found a positive correlation in 14 patients between ER and DR and survival: r=0.6754 and P=0.008, and r=0.5755 and P=0.031, respectively. Our results suggest that Te-99m-MIBI might be used in routine practice to monitor the chemotherapeutic response in patients with primary lung cancer, especially when PET is not available.en_US
dc.description.sponsorshipEANMen_US
dc.identifier.doi10.1007/s002590100560
dc.identifier.endpage806en_US
dc.identifier.issn0340-6997
dc.identifier.issue7en_US
dc.identifier.pmid24770458en_US
dc.identifier.scopus2-s2.0-0034913682en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage799en_US
dc.identifier.urihttps://doi.org/10.1007/s002590100560
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22216
dc.identifier.volume28en_US
dc.identifier.wosWOS:000170132500003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlagen_US
dc.relation.ispartofEuropean Journal Of Nuclear Medicineen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLung Canceren_US
dc.subjectChemotherapeutic Responseen_US
dc.subjectTherapy Monitoringen_US
dc.subjectTc-99m-MIBIen_US
dc.subjectPositron-Emission-Tomographyen_US
dc.subjectFdg-Peten_US
dc.subjectNasopharyngeal Carcinomaen_US
dc.subjectBreast-Carcinomaen_US
dc.subjectP-Glycoproteinen_US
dc.subjectSestamibien_US
dc.subjectTherapyen_US
dc.subjectRecurrenten_US
dc.subjectFluorine-18-Fluorodeoxyglucoseen_US
dc.subjectExpressionen_US
dc.titleMonitoring the chemotherapeutic response in primary lung cancer using 99mTc-MIBI SPETen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu